Analysis of the Effect of Recombinant Human Brain Natriuretic Peptide Combined with Sacubitril Valsartan in the Treatment of Severe Heart Fail-ure
Objective To analyze the therapeutic effect of recombinant human brain natriuretic peptide combined with sacubitril valsartan in patients with severe heart failure.Methods A total of 60 patients with severe heart failure admit-ted to Renhuai Hospital of Traditional Chinese Medicine from July 2022 to July 2023 were randomly selected as the study objects and divided into control group(treated with sackubactril and valsartan)and observation group(treated with recombinant human brain natriuretic peptide plus sackubactril and valsartan)by random number table method,with 30 cases in each group.The effective rate,cardiac function,serum indexes and the incidence of adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 96.67%,which was higher than that of the control group(70.00%),and the difference was statistically significant(x2=7.680,P<0.05).Af-ter treatment,compared with control group,the heart rate and left ventricular end-diastolic diameter in observation group were lower,and left ventricular ejection fraction was higher,and the differences were statistically significant(all P<0.05).After treatment,the levels of cardiacmuscle troponin T and N terminal Pro B trpe natriuretic peptide in ob-servation total group were lower than those in control group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion During the treatment of patients with severe heart failure,the joint use of sacubitril valsartan and recombinant human brain natriuretic peptide will improve cardiac function,reduce the relevant serum indexes of the patients,and the therapeutic safety as well as the effectiveness of the treatment are guar-anteed.
Recombinant human brain natriuretic peptideSacubitril valsartanTreatmentSevere heart failureTherapeutic efficacy
NETL
NSTL
万方数据
